Cargando…
Cyclovirobuxine D pretreatment ameliorates septic heart injury through mitigation of ferroptosis
Myocardial dysfunction is a frequent complication in patients with severe sepsis. However, effective drugs for the prevention of myocardial dysfunction and the molecular mechanisms of the disease remain elusive. The present study demonstrated that Cyclovirobuxine D (CVB-D) could improve cardiac dysf...
Autores principales: | Wang, Jianxin, Guan, Peng, Chen, Yu, Xu, Meng, Wang, Na, Ji, Ensheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375449/ https://www.ncbi.nlm.nih.gov/pubmed/37522059 http://dx.doi.org/10.3892/etm.2023.12106 |
Ejemplares similares
-
Cyclovirobuxine D Ameliorates Experimental Diabetic Cardiomyopathy by Inhibiting Cardiomyocyte Pyroptosis via NLRP3 in vivo and in vitro
por: Gao, Ge, et al.
Publicado: (2022) -
Canagliflozin mitigates ferroptosis and ameliorates heart failure in rats with preserved ejection fraction
por: Ma, Sai, et al.
Publicado: (2022) -
Dexmedetomidine alleviated sepsis-induced myocardial ferroptosis and septic heart injury
por: Wang, Chunyan, et al.
Publicado: (2020) -
Cyclovirobuxine D Induces Apoptosis and Mitochondrial Damage in Glioblastoma Cells Through ROS-Mediated Mitochondrial Translocation of Cofilin
por: Zhang, Lin, et al.
Publicado: (2021) -
Design and optimization of self-nanoemulsifying drug delivery systems for improved bioavailability of cyclovirobuxine D
por: Ke, Zhongcheng, et al.
Publicado: (2016)